Basiliximab Versus Daclizumab Combined With Triple Immunosuppression in Deceased Donor Renal Graft Recipients

Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996

Sundaram Hariharan, Christopher P. Johnson, Barbara A. Bresnahan et al. · New England Journal of Medicine · 2000 · 1.8K citations

Medicine, Nephrology, Surgery +11

Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation

F. Vincenti, Robert L. Kirkman, Susan Light et al. · New England Journal of Medicine · 1998 · 876 citations · Full text

Medicine, Immunology, Pharmacology +17

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

Björn Nashan, Richard H. Moore, P L Amlot et al. · The Lancet · 1997 · 762 citations

Life Sciences, Immunology, Nephrology +15

REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

Barry D. Kahan, P. R. Rajagopalan, Michael Hall · Transplantation · 1999 · 483 citations

Life Sciences, Immunology, Pharmacology +17

EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTION

Giacomo Basadonna, Arthur J. Matas, K. Gillingham et al. · Transplantation · 1993 · 365 citations

Medicine, Nephrology, Surgery +11